HOVON HO91
Archived
Main info
- Identifier:
- HO91 NHL
- Sponsor:
- HOVON
- Working group party:
- Lymphoma
- Stage:
- 1st Line
- Included patients:
-
116(of 116)
- Active sites:
-
23(of 23)
- Title:
ACT 2/HOVON 91 T-NHL: Alemtuzumab and chemotherapy in T-cell lymphoma (ACT): CHOP 14 with or without the monoclonal ant-CD52 antibody Alemtuzumab in elderly patients.
Timeline
Scheduled
Actual
2007
01 Oct
Activated
2007
12 Oct
FPI
2016
31 Mar
CloseoutInProgressLastPtOutActualStart
2021
28 Apr
Archived
News
This study has been closed on 2016-03-31
Details
- Phase:
- Prospective randomized Phase III study
- Monitoring Type:
- Not any more
- Objectives:
Participating Sites
Site
23 results
Order by
Accrual rate
Activation date
Non-HOVON-Sites
86
NL-Amsterdam-VUMC
4
NL-Rotterdam-EMCDANIEL
3
NL-Leiden-LUMC
3
NL-Maastricht-MUMC
3
NL-Rotterdam-ERASMUSMC
3
NL-Groningen-UMCG
2
BE-Antwerpen-ZNASTUIVENBERG
2
BE-Charleroi-GHDC
2
BE-Bruxelles-STLUC
2
NL-Enschede-MST
2
NL-Nieuwegein-ANTONIUS
1
NL-Den Haag-HAGA
1
NL-Amersfoort-MEANDERMC
1
BE-Roeselare-AZDELTA
1
NL-Geldrop-STANNA
NL-Dordrecht-ASZ
BE-Antwerpen-ZNAMIDDELHEIM
BE-Leuven-UZLEUVEN
NL-Zwolle-ISALA
NL-Nijmegen-RADBOUDUMC
NL-Amsterdam-AMC
BE-Ottignies-CSPO
= Active hospitals 
= Inactive hospitals